Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma. A Multicenter Phase II Trial
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Nelfinavir (Primary) ; Bortezomib; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 28 Sep 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Jun 2017 Biomarkers information updated
- 06 Dec 2016 Primary endpoint (Response rate based on best response observed during the trial) has been met, according to the abstract presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.